Please login to the form below

Not currently logged in
Email:
Password:

Flu vaccine subsidy for Takeda

Takeda Pharmaceutical is to receive a 23.9bn Yen subsidy from the Japanese government as part of a scheme to support the development and production of new influenza vaccines

Takeda Pharmaceutical is to receive a 23.9bn Yen (€215m) subsidy from the Japanese government as part of a scheme to support the development and production of new influenza vaccines.

The company's current influenza-related projects include an agreement with Baxter International to develop the proprietary Vero cell culture-based influenza vaccine technology.

Takeda has already introduced the technology into its experimental production facilities Hikari City having received a similar subsidy in 2010.

The extra funding will enable Takeda to continue the development work it had commenced and make preparations for full-scale manufacturing, including constructing a commercial production facility at the Hikari plant.

A new drug approval for an influenza vaccine is expected by the end of the financial year 2013, according to Takeda.

23rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics